[go: up one dir, main page]

AR057181A1 - Nueva forma de dosificacion de combinacion - Google Patents

Nueva forma de dosificacion de combinacion

Info

Publication number
AR057181A1
AR057181A1 ARP060105217A ARP060105217A AR057181A1 AR 057181 A1 AR057181 A1 AR 057181A1 AR P060105217 A ARP060105217 A AR P060105217A AR P060105217 A ARP060105217 A AR P060105217A AR 057181 A1 AR057181 A1 AR 057181A1
Authority
AR
Argentina
Prior art keywords
acetylsalicylic acid
prevention
dosage form
new combination
medicine
Prior art date
Application number
ARP060105217A
Other languages
English (en)
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38092508&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR057181(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astra Ab filed Critical Astra Ab
Publication of AR057181A1 publication Critical patent/AR057181A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Preparacion farmacéutica oral para el uso en la prevencion o la reduccion de complicaciones gastrointestinales asociadas con el uso de ácido acetil salicílico. Forma farmacéutica oral fija que consiste en un inhibidor de la bomba de protones, en combinacion con ácido acetil salicílico. Método para su elaboracion, y a su uso en medicina. Combinacion específica que comprende esomeprazol o una de sus sales alcalinas, o una de las formas hidratadas de cualquiera de estos, y ácido acetil salicílico, para el uso como un medicamento en la prevencion de sucesos vasculares tromboembolicos, tales como infarto de miocardio o accidente cerebrovascular; y en la prevencion o reduccion de complicaciones gastrointestinales asociadas con el uso de ácido acetil salicílico.
ARP060105217A 2005-11-30 2006-11-27 Nueva forma de dosificacion de combinacion AR057181A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74098105P 2005-11-30 2005-11-30
US81888606P 2006-07-06 2006-07-06

Publications (1)

Publication Number Publication Date
AR057181A1 true AR057181A1 (es) 2007-11-21

Family

ID=38092508

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060105217A AR057181A1 (es) 2005-11-30 2006-11-27 Nueva forma de dosificacion de combinacion

Country Status (14)

Country Link
US (2) US20070122470A1 (es)
EP (1) EP1957081A4 (es)
JP (1) JP2009517466A (es)
KR (1) KR20080070841A (es)
AR (1) AR057181A1 (es)
AU (1) AU2006321007A1 (es)
CA (1) CA2628907A1 (es)
EC (1) ECSP088490A (es)
IL (1) IL191312A0 (es)
NO (1) NO20082744L (es)
RU (1) RU2008121767A (es)
TW (1) TW200803871A (es)
UY (1) UY29975A1 (es)
WO (1) WO2007064274A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9600070D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
SE510650C2 (sv) 1997-05-30 1999-06-14 Astra Ab Ny förening
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
AR057181A1 (es) * 2005-11-30 2007-11-21 Astra Ab Nueva forma de dosificacion de combinacion
US9265732B2 (en) * 2006-03-06 2016-02-23 Pozen Inc. Dosage forms for administering combinations of drugs
WO2009147178A2 (en) * 2008-06-04 2009-12-10 Nycomed Gmbh Novel medical use of substituted pyridin-2-ylmethylsulphinyl-1h-benzimidazoles
BRPI0918492A2 (pt) * 2008-09-09 2015-12-01 Astrazeneca Ab uso de naproxen, ou sal farmaceuticamente aceitável do mesmo, e esomeprazol, ou sal farmaceuticamente aceitável do mesmo
EP2331084A4 (en) * 2008-10-06 2014-01-22 Jubilant Life Sciences Ltd PHARMACEUTICAL COMPOSITION WITH AMORPHIC ESOMEPRAZOL AND METHOD OF DOSING THEREOF AND METHOD THEREFOR
WO2010122583A2 (en) * 2009-04-24 2010-10-28 Rubicon Research Private Limited Oral pharmaceutical compositions of acid labile substances
US20100305163A1 (en) * 2009-05-20 2010-12-02 Pramod Dattatray Yedurkar Pharmaceutical formulations comprising nsaid and proton pump inhibitor drugs
AU2010263304A1 (en) 2009-06-25 2012-02-02 Astrazeneca Ab Method for treating a patient at risk for developing an NSAID-associated ulcer
NZ597534A (en) * 2009-06-25 2013-09-27 Pozen Inc Method for treating a patient in need of aspirin therapy
WO2011025673A1 (en) * 2009-08-26 2011-03-03 Aptapharma, Inc. Multilayer minitablets
WO2011144994A1 (en) * 2010-05-21 2011-11-24 Lupin Limited Pharmaceutical compositions of nsaid and acid inhibitor
AU2011337549A1 (en) * 2010-12-03 2013-07-04 Takeda Pharmaceutical Company Limited Orally disintegrating tablet
WO2012174731A1 (en) * 2011-06-24 2012-12-27 Cheng Haiyung Method and improved pharmaceutical composition for improving the absorption of an ester prodrug
TWI630002B (zh) 2011-11-30 2018-07-21 武田藥品工業股份有限公司 乾塗覆錠
EP2797600A4 (en) 2011-12-28 2015-09-16 Pozen Inc IMPROVED COMPOSITIONS AND METHODS OF DISTRIBUTING OMEPRAZOLE AND ACETYL SALICYLIC ACID
HK1221899A1 (en) * 2013-05-21 2017-06-16 Takeda Pharmaceutical Company Limited Oral disintegrating tablets
WO2015150943A1 (en) * 2014-03-29 2015-10-08 Wockhardt Limited Pharmaceutical composition of nsaid and ppi or salt thereof
CR20180119A (es) 2015-07-30 2018-03-21 Takeda Pharmaceuticals Co Tableta
JP7321744B2 (ja) * 2019-03-22 2023-08-07 キョーリンリメディオ株式会社 安定化されたエソメプラゾールマグネシウム水和物含有腸溶性固形製剤
CN119072315A (zh) * 2022-04-19 2024-12-03 韩美药品株式会社 包含乙酰水杨酸和质子泵抑制剂的药物组合物
KR20240043707A (ko) 2022-09-27 2024-04-03 한미약품 주식회사 아세틸살리실산 및 프로톤 펌프 저해제를 포함하는 약학적 조성물
KR102850540B1 (ko) * 2022-10-12 2025-08-26 일양약품주식회사 클로피도그렐 및 일라프라졸을 포함하는 복합제제

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4016744A (en) * 1975-05-28 1977-04-12 Hoffmann-La Roche Inc. Applied instrumentation providing tabletting compression force
US4263328A (en) * 1979-10-26 1981-04-21 General Foods Corporation Tableted gasified candy
IL75400A (en) * 1984-06-16 1988-10-31 Byk Gulden Lomberg Chem Fab Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
US4948581A (en) * 1989-02-17 1990-08-14 Dojin Iyaku-Kako Co., Ltd. Long acting diclofenac sodium preparation
US5204118A (en) * 1989-11-02 1993-04-20 Mcneil-Ppc, Inc. Pharmaceutical compositions and methods for treating the symptoms of overindulgence
SI1078628T1 (sl) * 1994-07-08 2009-04-30 Astrazeneca Ab Večenotska tabletirana dozirna oblika
SE9600070D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
GB2361185A (en) * 2000-04-10 2001-10-17 Nicholas J Wald Pharmaceutical formulation for the prevention of cardiovascular disease
US6544556B1 (en) * 2000-09-11 2003-04-08 Andrx Corporation Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and a proton pump inhibitor
US7029701B2 (en) * 2000-09-11 2006-04-18 Andrx Pharmaceuticals, Llc Composition for the treatment and prevention of ischemic events
EP2163241A1 (en) * 2001-06-01 2010-03-17 Pozen, Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
US8206741B2 (en) * 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
US6930099B2 (en) * 2001-09-07 2005-08-16 Advanced Medical Instruments Composition for the treatment and prevention of endothelial dysfunction
FR2845917B1 (fr) * 2002-10-21 2006-07-07 Negma Gild Composition pharmaceutique associant le tenatoprazole et un anti-inflammatoire
US20040121004A1 (en) * 2002-12-20 2004-06-24 Rajneesh Taneja Dosage forms containing a PPI, NSAID, and buffer
US20040131676A1 (en) * 2002-12-20 2004-07-08 Rajneesh Taneja Dosage forms containing a PPI, NSAID, and buffer
WO2004062552A2 (en) * 2003-01-09 2004-07-29 Galephar M/F Pharmaceutical composition containing a nsaid and a benzimidazole derivative
JP2005145894A (ja) * 2003-11-17 2005-06-09 Takeda Chem Ind Ltd 固形製剤
US20050163847A1 (en) * 2004-01-21 2005-07-28 Andrx Pharmaceuticals, Llc Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and an antiulcerative drug
CA2554271A1 (en) * 2004-02-10 2005-08-25 Santarus, Inc. Combination of proton pump inhibitor, buffering agent, and nonsteroidal anti-inflammatory agent
US20050227949A1 (en) * 2004-04-07 2005-10-13 Nasrola Edalatpour Compositions and methods for treatment of viral and bacterial infections
US20060177504A1 (en) * 2005-02-08 2006-08-10 Renjit Sundharadas Combination pain medication
AR057181A1 (es) * 2005-11-30 2007-11-21 Astra Ab Nueva forma de dosificacion de combinacion
WO2007078874A2 (en) * 2005-12-30 2007-07-12 Cogentus Pharmaceuticals, Inc. Oral pharmaceutical formulations containing non-steroidal anti-inflammatory drugs and acid inhibitors
AR066677A1 (es) * 2007-05-24 2009-09-02 Novartis Ag Formulacion de pasireotida. composicion farmaceutica para liberacion prolongada. microparticulas.

Also Published As

Publication number Publication date
IL191312A0 (en) 2008-12-29
UY29975A1 (es) 2007-06-29
US20070122470A1 (en) 2007-05-31
KR20080070841A (ko) 2008-07-31
WO2007064274A1 (en) 2007-06-07
TW200803871A (en) 2008-01-16
NO20082744L (no) 2008-08-28
US20100178334A1 (en) 2010-07-15
JP2009517466A (ja) 2009-04-30
RU2008121767A (ru) 2010-01-10
EP1957081A1 (en) 2008-08-20
AU2006321007A1 (en) 2007-06-07
EP1957081A4 (en) 2013-01-02
CA2628907A1 (en) 2007-06-07
ECSP088490A (es) 2008-06-30

Similar Documents

Publication Publication Date Title
AR057181A1 (es) Nueva forma de dosificacion de combinacion
ES2524320T3 (es) Composición para la prevención o el tratamiento de enfermedad asociada con trombo o émbolo
ES2502472T3 (es) Composición adhesiva para su uso en un inmunosensor
EP4563151A4 (en) PHARMACEUTICAL COMPOSITION COMPRISING A KRAS G12D INHIBITOR
CL2012003281A1 (es) Uso de compuestos específicos estimuladores y/o activadores de sgc; formulacion farmaceutica que comprende dichos compuestos; kit que comprende los compuestos, y uso para la prevencion y/o tratamiento de la esclerosis sistematica.
EA201200550A1 (ru) Фармацевтические композиции, включающие bi-1356 и метформин
CL2011001621A1 (es) Composicion farmaceutica oral de liberacion sostenida que comprende en una forma de dosificacion unitaria, una matriz hidrofilica, un opioide, una sal de un aine, y opcionalmente un surfactante aniónico; y uso para preparar medicamentos utiles en la prevencion, alivio o disminución del nivel del dolor y supresión de la tos.
EA201390814A1 (ru) Перорально распадающаяся таблетка
ECSP088889A (es) Forma nueva de administración de racecadotril
AR075369A1 (es) Comprimidos para terapia de combinacion para el tratamiento de infecciones virales.
PA8809601A1 (es) Combinación anti-retroviral
ES2531516T3 (es) Uso de escina
CL2007002494A1 (es) Composicion farmaceutica que comprende una pirimidina trisustituida en combinacion con un compuesto con propiedades inhibitorias de pde5; y uso en el tratamiento de una enfermedad que involucre vasoconstriccion.
CO6300935A2 (es) Formulaciones orales e inyectables de compuestos de tetraciclina
PA8850701A1 (es) Dispensor de medicamentos y su uso
HRP20110523T1 (hr) Fenotropil za profilaksu i liječenje hemoragičnog udara i akutne faze ishemičkog udara
CO6210807A2 (es) Composicion farmacetica que farmaceutica que contiene una combinacion de tramadol y ketoprofeno
CL2011000388A1 (es) Combinacion farmaceutica que comprende (6-dimetilaminometil-1-(3-metoxifenil)-ciclohexano-1,3-diol y un antiinflamatorio no esteroidal; forma de dosificacion; uso en el tratamiento de la osteoartritis y el dolor.
CL2015003561A1 (es) Composición farmacéutica para administración por vía oral para su uso para la prevención y/o el tratamiento de una enfermedad cardiovascular.
AR050903A1 (es) Metodo para la prevencion de trastornos tromboticos, embolicos y/o hemorragicos
AR085399A1 (es) Combinacion antitumoral que comprende cabazitaxel y cisplatino
ES2680293B1 (es) Composición farmacéutica que comprende ácido 2,5 - dihidroxibencenosulfónico o una de sus sales farmacéuticamente aceptables en forma de unidades individualizadas de suministro y procedimiento de fabricación correspondiente
AR085431A1 (es) Complejo de resinato de doxilamina
ES2422877B1 (es) Combinación y composición para el tratamiento de obesidad
CL2007001763A1 (es) Composicion farmaceutica en forma de una tableta multicapas que comprende una primera region que comprende una tetraciclina y un vehiculo, y una segunda region que comprende un tampon y un segundo vehiculo; formulacion acuosa; y uso para tratar o prevenir la mucositis oral.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal